Allen, CE, Li, L, Peters, TL, Leung, HC, Yu, A, Man, TK et al.. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 184: 4557-4567

Department of Pediatrics, Texas Children's Cancer Center and Hematology Service, Baylor College of Medicine, Houston, TX 77030, USA.
The Journal of Immunology (Impact Factor: 4.92). 03/2010; 184(8):4557-67. DOI: 10.4049/jimmunol.0902336
Source: PubMed


Langerhans cell histiocytosis (LCH) is a rare disease characterized by heterogeneous lesions containing CD207(+) Langerhans cells (LCs) and lymphocytes that can arise in almost any tissue and cause significant morbidity and mortality. After decades of research, the cause of LCH remains speculative. A prevailing model suggests that LCH arises from malignant transformation and metastasis of epidermal LCs. In this study, CD207(+) cells and CD3(+) T cells were isolated from LCH lesions to determine cell-specific gene expression. Compared with control epidermal CD207(+) cells, the LCH CD207(+) cells yielded 2113 differentially expressed genes (false discovery rate < 0.01). Surprisingly, the expression of many genes previously associated with LCH, including cell-cycle regulators, proinflammatory cytokines, and chemokines, were not significantly different from control LCs in our study. However, several novel genes whose products activate and recruit T cells to sites of inflammation, including SPP1 (osteopontin), were highly overexpressed in LCH CD207(+) cells. Furthermore, several genes associated with immature myeloid dendritic cells were overexpressed in LCH CD207(+) cells. Compared with the peripheral CD3(+) cells from LCH patients, the LCH lesion CD3(+) cells yielded only 162 differentially regulated genes (false discovery rate < 0.01), and the expression profile of the LCH lesion CD3(+) cells was consistent with an activated regulatory T cell phenotype with increased expression of FOXP3, CTLA4, and SPP1. Results from this study support a model of LCH pathogenesis in which lesions do not arise from epidermal LCs but from accumulation of bone marrow-derived immature myeloid dendritic cells that recruit activated lymphocytes.

Download full-text


Available from: Amos Gaikwad, Oct 16, 2014
18 Reads
  • Source
    • "However, recent discoveries question the model of LCH arising from transformed or pathologically activated epidermal Langerhans cells. The cell-specific gene expression signature in langerin + DCs within LCH lesions has been shown to be more consistent with immature myeloid DC precursors than epidermal Langerhans cells (Allen et al., 2010). Furthermore , mouse studies demonstrate that langerin is more promiscuous than previously appreciated (Ginhoux et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207(+) dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207(+) DCs. BRAF-V600E expression in tissue DCs did not define specific clinical risk groups but was associated with increased risk of recurrence. Strikingly, we found that patients with active, high-risk LCH also carried BRAF-V600E in circulating CD11c(+) and CD14(+) fractions and in bone marrow (BM) CD34(+) hematopoietic cell progenitors, whereas the mutation was restricted to lesional CD207(+) DC in low-risk LCH patients. Importantly, BRAF-V600E expression in DCs was sufficient to drive LCH-like disease in mice. Consistent with our findings in humans, expression of BRAF-V600E in BM DC progenitors recapitulated many features of the human high-risk LCH, whereas BRAF-V600E expression in differentiated DCs more closely resembled low-risk LCH. We therefore propose classification of LCH as a myeloid neoplasia and hypothesize that high-risk LCH arises from somatic mutation of a hematopoietic progenitor, whereas low-risk disease arises from somatic mutation of tissue-restricted precursor DCs.
    Journal of Experimental Medicine 03/2014; 212(2). DOI:10.1084/jem.20130977 · 12.52 Impact Factor
  • Source
    • "Laboratory tests upon diagnosis should include complete blood count, liver function tests, and cultures if infectious symptoms are present. Bone marrow aspiration and biopsy may be useful in the evaluation of cytopenias.15 Imaging should include a chest radiograph, and chest computed tomography should be obtained if pulmonary symptoms are present. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hemorrhagic pustules with a "blueberry muffin" appearance accompanied by respiratory failure in a neonate present a challenging differential diagnosis that includes infections and neoplasms. We present a case of multiorgan, multisite Langerhans cell histiocytosis (LCH), positive for the oncogenic BRAF V600E mutation, in a preterm neonate. Infants with LCH pose a diagnostic challenge due to their heterogeneous presentations. This case is unusual in that the newborn presented with severe multiorgan involvement. Due to the rare incidence, wide spectrum of clinical manifestations, and high mortality rate, clinicians must maintain a high index of suspicion for LCH.
    AJP Reports 10/2013; 3(2):63-6. DOI:10.1055/s-0033-1338168
  • Source
    • "LC preferentially expressed a small number of receptors, including CD207 (langerin), lipoprotein receptors (LSR and LDLR), and only a handful of genes primarily involved in immune processes (CCL22, CD70, CLU, COTL1, HLA-DQA, and TAPBL; the full list of genes preferentially expressed in LCs and DDCs: Supplementary Table S2 online). Migratory skin DCs and trypsinized skin DCs demonstrate strongly matching transcriptomes To confirm the relevance of these findings to the in vivo situation, we also challenged our model system against whole transcriptome data from DCs rapidly isolated from skin using a trypsinization protocol (Santegoets et al., 2008; Allen et al., 2010; Hutter et al., 2012; Harman et al., 2013; Supplementary Table S3 online). Comparison of the genes differentially expressed in either LCs or DDCs revealed the same pattern of expression in both the migratory and trypsinized models (Supplementary Figure 2 online). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Langerhans cells (LCs) are professional antigen presenting cells (APCs) residing in the epidermis. Despite their high potential to activate T lymphocytes, current understanding of human LC biology is limited. Genome-wide comparison of the transcriptional profiles of human skin migratory CD1a+ LCs and CD11c+ dermal dendritic cells (DDCs) demonstrated significant differences between these 'dendritic cell' types, including preferential expression of 625 genes (P<0.05) in LC and 914 genes (P<0.05) in DDC. Analysis of the temporal regulation of molecular networks activated after stimulation with TNF-α confirmed the unique molecular signature of LCs. Although LCs conformed to the phenotype of professional APC, inflammatory signalling activated primarily genes associated with cellular metabolism and mitochondrial activation (e.g. CYB561, MRPS35), cell membrane re-organisation and antigen acquisition and degradation (CAV1, PSMD14) (P<0.05-P<0.0001). Conversely, TNF-α induced classical activation in DDCs with early down-regulation of surface receptors (MRC1, C-type lectins), and subsequent up-regulation of cytokines, chemokines (IL1a, IL1b, CCL18) and matrix metalloproteinases (MMP1, MMP3, MMP9), (P<0.05-P<0.0001). Functional interference of caveolin abrogated LCs superior ability to cross-present antigens to CD8+ T lymphocytes, highlighting the importance of these networks to biological function. Taken together these observations support the idea of distinct biological roles of cutaneous DC types.Journal of Investigative Dermatology accepted article preview online, 4 September 2013; doi:10.1038/jid.2013.375.
    Journal of Investigative Dermatology 09/2013; 134(3). DOI:10.1038/jid.2013.375 · 7.22 Impact Factor
Show more